Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Colorectal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Thoracic Neoplasms 1Neoplasms 1Lymphoma, Non-Hodgkin 1Lung Neoplasms 1Lung Diseases 1Colonic Neoplasms 1Carcinoma, Bronchogenic 1Bronchial Neoplasms 1

Interventions

Carboplatin 5Pemetrexed 4pembrolizumab 3osimertinib 3entinostat 3selpercatinib 2durvalumab 2camrelizumab 2Erlotinib Hydrochloride 2sotorasib 1repotrectinib 1pralsetinib 1patritumab 1napabucasin 1exemestane 1cobimetinib 1ceralasertib 1capmatinib 1alectinib 1aflutinib 1Toll-Like Receptor 1 1TNFSF10 protein, human 1Patient Reported Outcome Measures 1Paclitaxel 1Injections 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Bronchial Neoplasms × TNFSF10 protein, human × Clear all
NCT03083743 2017-03-20

A Phase III Trial of Recombinant Human Apo-2 Ligand for Injection

Shanghai Gebaide Biotechnology Co., Ltd.

Phase 3 Unknown
417 enrolled
Thoracic

Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms, Neoplasms, Thoracic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡